Calcium ionophore:: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells

被引:33
作者
Waclavicek, M
Berbr, A
Oehler, L
Stöckl, J
Schloegl, E
Majdic, O
Knapp, W
机构
[1] Univ Vienna, Inst Immunol, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Internal Med, Div Haematol, A-1090 Vienna, Austria
[3] Hanusch Hosp, Dept Med 3, Vienna, Austria
关键词
acute myelogenous leukaemia; differentiation; dendritic cells; immunotherapy;
D O I
10.1046/j.1365-2141.2001.02970.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Blood monocytes and CD34(+) haemopoietic progenitor cells, as, well as certain leukaemic cell lines, acquire characteristics of mature dendritic cells (DC) after stimulation with calcium ionophore (CI). We studied whether the in vitro treatment of primary human acute myelogenous leukaemia (AML) cells with CI leads to differentiation towards DC. Blast cells derived from nine AML patients were cultured in the presence of either CI or an established differentiation cocktail consisting of granulocyte-macrophage colony-stimulating factor plus interleukin 4 and tumour necrosis factor-alpha for 5-7 d. Microscopic examination revealed that under both conditions, AML cells were shifted along the DC pathway. In seven out of nine cases, CI-cultivation led to a higher proportion of cells with dendritic morphology. The percentage of CD40 and CD86 expressing cells was significantly increased upon CI treatment compared with cytokine-cultured cells. DC molecules as CD80 and CD83 were up-regulated upon calcium mobilization of AML cells in four out of nine samples. In four cases, CI-treated stimulator cells induced an enhanced proliferative allogeneic T-cell response compared with cytokine-treated stimulator cells. In conclusion, these data demonstrate that CI treatment is an alternative in vitro strategy to differentiate human AML cells into DC.
引用
收藏
页码:466 / 473
页数:8
相关论文
共 26 条
[1]   B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma [J].
Antonia, SJ ;
Seigne, JD .
WORLD JOURNAL OF UROLOGY, 2000, 18 (02) :157-163
[2]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[3]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[4]   Dendritic cells [J].
Bell, D ;
Young, JW ;
Banchereau, J .
ADVANCES IN IMMUNOLOGY, VOL. 72, 1999, 72 :255-324
[5]   The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses [J].
Brouwer, RE ;
van der Hoorn, M ;
Kluin-Nelemans, HC ;
van Zelderen-Bhola, S ;
Willemze, R ;
Falkenburg, JHF .
HUMAN IMMUNOLOGY, 2000, 61 (06) :565-574
[6]  
Cao L, 1998, Stem Cells, V16 Suppl 1, P251
[7]  
Charbonnier A, 1999, EUR J IMMUNOL, V29, P2567, DOI 10.1002/(SICI)1521-4141(199908)29:08<2567::AID-IMMU2567>3.0.CO
[8]  
2-S
[9]   Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses [J].
Choudhury, A ;
Liang, JC ;
Thomas, EK ;
Flores-Romo, L ;
Xie, QS ;
Agusala, K ;
Sutaria, S ;
Sinha, I ;
Champlin, RE ;
Claxton, DF .
BLOOD, 1999, 93 (03) :780-786
[10]   Human leukemia-derived dendritic cells: Ex-vivo development of specific antileukemic cytotoxicity [J].
Choudhury, A ;
Toubert, A ;
Sutaria, S ;
Charron, D ;
Champlin, RE ;
Claxton, DF .
CRITICAL REVIEWS IN IMMUNOLOGY, 1998, 18 (1-2) :121-131